Mandy Jackson

San Diego

Managing Editor, US Commercial News at Scrip

Managing Editor, US Commercial News at The Pink Sheet

I am Managing Editor, US Commercial News, for the Citeline Commercial publications Scrip and The Pink Sheet. Views expressed here are strictly my own.

Featured in: Favicon

informa.com (+4) Favicon

pharmamedtechbi.com Favicon

clinicalleader.com Favicon

citeline.com Favicon

xconomy.com Favicon

invivo.citeline.com

Articles

Business Financing & Market Trends

6 days ago | insights.citeline.com | Mandy Jackson |Kevin Grogan |Joseph Haas |Andrew McConaghie

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings. HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.
Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

6 days ago | insights.citeline.com | Mandy Jackson

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health InvestmentsApril Mega-Round Count Ties with Six In MarchPrivate Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.
HAYA Raises $65m To Take First Long Non-Coding RNA Program Into The Clinic

1 week ago | insights.citeline.com | Mandy Jackson

HAYA Raises $65m To Take First Long Non-Coding RNA Program Into The ClinicFirst Financing Since $20m Seed Round In 2021HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity. HAYA is searching the dark genome for long non-coding RNA targets (Shutterstock)
Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER Appointment

1 week ago | insights.citeline.com | Mandy Jackson

Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER AppointmentValuation Down 42.3% Over Two DaysSarepta’s stock price was battered after Vinay Prasad was appointed to lead the US FDA’s CBER, then the company’s shares were bruised when Q1 Elevidys sales came in below consensus. Sarepta faced a one-two punch on 6 May when it reported Q1 earnings (Shutterstock)
Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches

1 week ago | insights.citeline.com | Mandy Jackson

Vertex Sinks On Below-Consensus Revenue, Limited Sales From New LaunchesNext Launches In Late 2026 Or BeyondVertex is in need of diversification, but in addition to its lower-than-expected Q1 revenue, sales of the company’s newest CF drug Alyftrek and pain medicine Journavx disappointed. Vertex's two new launches missed Q1 analyst targets (Shutterstock)
Finance Watch: Unity Lays Off All Employees As It Evaluates Alternatives

1 week ago | insights.citeline.com | Mandy Jackson

Finance Watch: Unity Lays Off All Employees As It Evaluates AlternativesJob Cuts At Pliant, Arvinas, Phathom And OthersRestructuring Edition: Unity unveiled more Phase IIb data for lead asset UBX1325 along with plans to shed its workforce while seeking a partner for it and other drugs. Also, Ono is consolidating US employees at one site, Entrada is cutting its workforce by 20% and other recent strategic shifts.
Finance Watch: Biohaven Gains Up To $600m In Fresh Capital

1 week ago | insights.citeline.com | Mandy Jackson

Finance Watch: Biohaven Gains Up To $600m In Fresh CapitalGeoVax, Vaxart BARDA Funding DisruptedPublic Company Edition: Biohaven secured $250m up front from Oberland Capital to support its future US troriluzole launch after pulling its EU filing. Also, Procaps arranged $130m in private equity and Rezolute grossed $96.9m in a rare follow-on offering, among other financings.
Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

2 weeks ago | insights.citeline.com | Mandy Jackson

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff ImpactQ1 Revenue Grew, Beat ConsensusBiogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US. With its next big Phase III readouts in 2026 and beyond, Leqembi remains the biggest focus for Biogen investors (Shutterstock)
Amgen Under Pressure, But Seeing Gains Ahead Of Obesity Readouts

2 weeks ago | insights.citeline.com | Mandy Jackson

Amgen Under Pressure, But Seeing Gains Ahead Of Obesity ReadoutsDenosumab Biosimilars Impact Expected Later This YearMariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025. Gains from products besides Prolia and Xgeva will grow Amgen's 2025 sales after denosumab biosimilars puts pressure on total revenue (Shutterstock)
BridgeBio Takes A Victory Lap With First Full Quarter Of Attruby Sales

2 weeks ago | insights.citeline.com | Mandy Jackson

BridgeBio Takes A Victory Lap With First Full Quarter Of Attruby SalesExpecting Little Impact From Recent Alnylam OptionBridgeBio reported $36.7m in Q1 2025 sales of its ATTR-CM drug Attruby, tripling consensus forecasts. Vyndaquel-maker Pfizer acknowledged the product’s impact during the quarter. BridgeBio's Attruby sped through Q1 sales expectations in ATTR-CM (Shutterstock)